Drugs That Cause or Treat Weight Gain

Why Some Medications Cause Weight Gain

Drug-induced weight gain is not a single mechanism but a set of overlapping pathways. Medications can increase appetite through histamine H1 or serotonin 5-HT2C receptor blockade, slow resting metabolic rate, promote fat storage via insulin sensitization, or cause fluid retention through mineralocorticoid effects. The result is that a patient following the same diet before and after starting a new drug can still gain measurable weight.

A 2015 BMJ review estimated that prescription medications contribute to weight gain in roughly 10-15% of adults with obesity, making drug-induced gain one of the most overlooked and correctable contributors to the obesity epidemic. The effect is dose-dependent for many agents and often reversible with substitution or discontinuation. Recognizing which drug classes carry this risk is a prerequisite for any meaningful weight-management plan.

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity explicitly recommends that clinicians "review the patient's medication list and, whenever possible, substitute medications that are weight-neutral or associated with weight loss for those that are associated with weight gain" [1]. This single intervention, done before adding any anti-obesity drug, can prevent or reverse 2 to 10 kg of iatrogenic weight.

Antipsychotics and Mood Stabilizers

Atypical antipsychotics are among the strongest weight-promoting medications prescribed today. Olanzapine and clozapine sit at the top of the liability spectrum, while aripiprazole and ziprasidone are considered weight-neutral alternatives.

A landmark meta-analysis by Allison et al. in the American Journal of Psychiatry (1999) quantified mean weight gain after 10 weeks of standard dosing: clozapine +4.5 kg, olanzapine +4.2 kg, quetiapine +2.2 kg, and risperidone +2.1 kg, compared with +0.1 kg for ziprasidone [2]. These numbers compound over months to years of maintenance treatment. In the CATIE trial (N=1,493), 30% of olanzapine-treated patients with schizophrenia gained ≥7% of baseline body weight over 18 months [3].

Mood stabilizers show a similar split. Lithium and valproate carry meaningful weight-gain risk (mean +4 to 6 kg in the first year), while lamotrigine is essentially weight-neutral [4]. For patients on valproate who develop metabolic complications, the American Psychiatric Association recommends considering a switch to lamotrigine or carbamazepine when clinically appropriate.

Dr. David Allison, then at Columbia University, noted in his 1999 analysis: "Clinicians should consider potential weight gain when choosing among antipsychotic agents, particularly for patients already at metabolic risk" [2]. That guidance remains unchanged a quarter-century later.

Antidepressants: Not All Are Equal

The weight impact of antidepressants varies sharply by class and individual agent. Mirtazapine, paroxetine, and older tricyclics (amitriptyline, nortriptyline) are most consistently linked to gain. SSRIs as a class tend to be weight-neutral in the short term but may cause modest gain (1 to 2 kg) after 6 to 12 months of use.

A large retrospective cohort study published in the BMJ (2024, N=183,118) found that antidepressant users gained an average of 1.5 kg more than non-users over 10 years, with mirtazapine showing the highest risk at +2.4 kg above controls [5]. Bupropion stood out as the only antidepressant consistently associated with weight loss (mean -1.3 kg vs. controls), which is one reason it appears in the combination anti-obesity drug naltrexone-bupropion (Contrave).

For patients who need antidepressant therapy and are concerned about weight, bupropion or fluoxetine (which is mildly anorexigenic in the first 6 months) are reasonable first-line considerations, provided they match the psychiatric indication.

Corticosteroids, Insulin, and Other Common Culprits

Systemic corticosteroids cause weight gain through increased appetite, visceral fat deposition, fluid retention, and insulin resistance. Even short courses (prednisone ≥7.5 mg/day for 4 to 8 weeks) can add 1.5 to 8 kg, depending on dose and duration [6]. Patients on chronic glucocorticoids for autoimmune conditions frequently develop cushingoid features including central adiposity.

Insulin therapy, while life-saving for type 1 diabetes and often necessary in advanced type 2 diabetes, causes an average weight increase of 2 to 4 kg in the first year [7]. This gain is partly due to reduced glycosuria (the body retains calories that were previously lost as glucose in urine) and partly due to insulin's anabolic effects on adipose tissue.

Other notable weight-promoting medications include:

• Beta-blockers (atenolol, metoprolol): mean gain of 1.2 kg over 6 months, possibly via reduced thermogenesis and exercise intolerance [8]
• Gabapentin and pregabalin: 5 to 10% of users gain ≥7% body weight, likely through increased appetite signaling [9]
• Sulfonylureas (glipizide, glyburide): +2 to 3 kg gain in the first year, driven by hyperinsulinemia
• Hormonal contraceptives: depot medroxyprogesterone acetate (Depo-Provera) is linked to 2 to 3 kg gain; combined oral contraceptives show minimal effect in Cochrane meta-analyses [10]

FDA-Approved Anti-Obesity Medications

Five medications currently hold FDA approval for long-term weight management. Each requires concurrent lifestyle modification (reduced-calorie diet plus increased physical activity) and is indicated for adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity.

Semaglutide 2.4 mg (Wegovy). In the STEP-1 trial (N=1,961), once-weekly subcutaneous semaglutide produced 14.9% mean body-weight loss at 68 weeks vs. 2.4% with placebo [11]. The SELECT cardiovascular outcomes trial (N=17,604) showed a 20% reduction in major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and overweight or obesity but without diabetes [12].

Tirzepatide (Zepbound). This dual GIP/GLP-1 receptor agonist produced dose-dependent weight loss in SURMOUNT-1 (N=2,539): 15.0% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg vs. 3.1% with placebo at 72 weeks [13]. More than one in three participants on the 15 mg dose lost ≥25% of body weight.

Phentermine-topiramate ER (Qsymia). The CONQUER trial (N=2,487) demonstrated 9.8% mean weight loss with the top dose at 56 weeks vs. 1.2% for placebo [14]. This combination remains one of the most cost-effective oral options.

Naltrexone-bupropion ER (Contrave). The COR-I trial showed 6.1% mean weight loss vs. 1.3% with placebo at 56 weeks [15]. This agent is oral, does not require injection, and has a favorable profile for patients with concurrent depression.

Orlistat (Xenical/Alli). The oldest approved option, orlistat blocks pancreatic lipase and reduces dietary fat absorption by roughly 30%. The XENDOS trial (N=3,305) showed 5.8 kg more weight loss than placebo at 4 years and a 37% reduction in type 2 diabetes incidence [16].

GLP-1 Receptor Agonists: Mechanism and Clinical Positioning

GLP-1 receptor agonists work by mimicking incretin hormones released after eating. They slow gastric emptying, suppress glucagon secretion, and act on hypothalamic appetite centers to reduce hunger. The result is that patients eat less without the constant sensation of deprivation that undermines calorie-restricted diets.

The 2023 American Gastroenterological Association (AGA) clinical practice guideline on pharmacological interventions for adults with obesity recommends semaglutide 2.4 mg or tirzepatide as first-line pharmacotherapy for patients who meet BMI criteria and have not responded adequately to lifestyle modification alone [17]. The AGA specifically notes that "the magnitude of weight loss with these newer agents approaches that of some bariatric surgical procedures".

Real-world adherence matters. A 2024 analysis of U.S. pharmacy claims data found that roughly 40% of patients prescribed GLP-1 agonists for weight loss discontinue within the first 12 months, primarily due to cost, gastrointestinal side effects, or supply constraints [18]. Patients who persist beyond 6 months tend to achieve results closer to the trial data.

Weight-Neutral Medication Alternatives

Before adding an anti-obesity medication, a clinician should audit the current prescription list for weight-promoting agents that have weight-neutral substitutes within the same therapeutic class. This table summarizes common swaps supported by clinical evidence:

• Atypical antipsychotics: switch from olanzapine or quetiapine to aripiprazole or ziprasidone
• Antidepressants: switch from mirtazapine or paroxetine to bupropion or sertraline
• Diabetes agents: switch from sulfonylureas or insulin (when possible) to metformin, SGLT2 inhibitors (empagliflozin, dapagliflozin), or GLP-1 agonists
• Beta-blockers: switch from atenolol to carvedilol or nebivolol (both have more favorable metabolic profiles)
• Anticonvulsants: switch from gabapentin or valproate to topiramate or lamotrigine
• Contraceptives: switch from depot medroxyprogesterone to an IUD or combined oral contraceptive

The Endocrine Society guideline emphasizes that medication substitution alone can produce clinically meaningful weight reduction of 2 to 5% in patients whose gain was primarily iatrogenic [1].

When to Seek Medical Evaluation for Weight Gain

Unexplained weight gain of ≥5% of body weight over 6 to 12 months, or rapid gain (≥2 kg in a week) accompanied by edema or shortness of breath, warrants medical evaluation. Endocrine causes (hypothyroidism, Cushing syndrome, polycystic ovary syndrome), cardiac causes (heart failure with fluid retention), and medication effects should all be considered.

The U.S. Preventive Services Task Force recommends that clinicians screen all adults for obesity by measuring BMI at routine visits and offer or refer patients with a BMI ≥30 to intensive, multicomponent behavioral interventions [19]. The threshold for pharmacotherapy begins when behavioral intervention alone produces <5% weight loss after 3 to 6 months.

Lab workup for unexplained weight gain typically includes TSH (to exclude hypothyroidism), fasting glucose and HbA1c (to screen for insulin resistance or diabetes), a lipid panel, and morning cortisol if Cushing syndrome is suspected. For women with irregular menses and weight gain, testosterone, DHEA-S, and pelvic ultrasound help evaluate for PCOS.

Combination and Emerging Therapies

The anti-obesity pipeline is expanding rapidly. Survodutide (a dual glucagon/GLP-1 agonist) showed 18.7% placebo-adjusted weight loss at 46 weeks in its phase 2 trial [20]. Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, produced up to 24.2% mean weight loss at 48 weeks in a phase 2 study published in the New England Journal of Medicine [21].

Combination approaches are also gaining traction. Pairing a GLP-1 agonist with an SGLT2 inhibitor (e.g., semaglutide plus empagliflozin) addresses both appetite and renal glucose excretion, often yielding additive weight loss of 2 to 3% beyond GLP-1 monotherapy [22]. For patients already on anti-obesity pharmacotherapy who plateau, adding topiramate or switching to a dual- or triple-agonist may break the stall.

The key clinical principle: anti-obesity medications are most effective when iatrogenic weight gain has been minimized first and when behavioral foundations (nutrition, activity, sleep optimization) are already in place.